Efficacy of the Enteroadsorbent Silicol®gel in Adults with Irritable Bowel Syndrome Subtypes IBS-D or Mixed: Observational Open-Label Study
Gastroenterology Research and Practice · 16.12.2023 · 2023 · 1-14
DOI: 10.1155/2023/3432763 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastroenterology Research and Practice, erschienen am 16.12.2023. Verfasst von Gordon Crawford und 3 weiteren Autor:innen. Beteiligte Einrichtung: CPS Research, McCafferty House, 99 Firhill Road, Glasgow, UK G20 7BE. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FW Medical Ltd.
Abstract (Originalsprache)
Background
Irritable bowel syndrome (IBS) is a common chronic gut-brain interaction disorder with limited effective treatment options. Intestinal adsorbents have a high adsorption capacity for gut irritants and may provide nonpharmacological alternatives.
Objectives
This post marketing study is aimed at providing up-to-date evidence to support the safety and efficacy in normal use of an established medical device for IBS treatment.
Methods
In this open-label, observational study, adults with IBS with predominant diarrhoea (IBS-D) or IBS with mixed bowel habits (IBS-M), according to Rome IV criteria, received 4 weeks of treatment with the enteroadsorbent Silicol®gel, a CE-certified, licenced, medical device containing colloidal silicic acid. Eligible participants were assessed at baseline (visit 1; in-clinic) and after 1 (visit 2; telephone), 2 (visit 3; telephone), and 4 (visit 4; in-clinic) weeks of treatment. The primary endpoint was the proportion of participants with an overall reduction in the IBS severity scoring system IBS SSS > 50 , representing clinically meaningful improvement. Key secondary endpoints were a reduction in common IBS symptoms and improved quality of life (QoL).
Results
Among the 67 treated participants (IBS-D: 37; IBS-M: 30), 65 completed the study. At visit 4, 83.6% (56/67) of participants achieved a reduction in IBS SSS > 50 . The mean (standard deviation [SD]) IBS SSS was 323.4 (55.7) at visit 1 and 160.3 (90.3) at visit 4 (overall change: -163.1 (101.7); 95% confidence interval [CI] 138.3, 187.9, p < 0.001 ). Compared with visit 1, significant reductions in the severity of all key IBS symptoms and overall improvement in QoL were observed at visit 4 ( p < 0.001 ), with improvements observed from visits 1 and 2.
Conclusions
In this open-label study of participants with IBS-D and IBS-M, Silicol®gel provided clinically significant improvement in IBS symptoms, demonstrating that enteroadsorbents may be clinically beneficial in this population.
Autor:innen und Institutionen
- CPS Research, McCafferty House, 99 Firhill Road, Glasgow, UK G20 7BE.
- Department of Mathematics and Statistics, University of Strathclyde, 26 Richmond Street, Glasgow, UK G1 1XH.
- NHS, Greater Glasgow and Clyde, 1055 Great Western Road, Glasgow, UK G12 0XH.
- FW Medical Ltd, West of Scotland Science Park, Kelvin Campus, Block 6, Glasgow, UK G20 0SP.
ORCID-Profile: Chris G Hatton
Förderung
- FW Medical Ltd
Zitieren
APA
Crawford, G., Taylor, R., Young, D., & Hatton, C. G. (2023). Efficacy of the Enteroadsorbent Silicol®gel in Adults with Irritable Bowel Syndrome Subtypes IBS-D or Mixed: Observational Open-Label Study. Gastroenterology Research and Practice, 2023, 1-14. https://doi.org/10.1155/2023/3432763
Vancouver
Crawford G, Taylor R, Young D, Hatton CG. Efficacy of the Enteroadsorbent Silicol®gel in Adults with Irritable Bowel Syndrome Subtypes IBS-D or Mixed: Observational Open-Label Study. Gastroenterology Research and Practice. 2023;2023:1-14. doi:10.1155/2023/3432763
BibTeX
@article{Crawford2023,
author = {Crawford, Gordon and Taylor, Rory and Young, David and Hatton, Chris G},
title = {Efficacy of the Enteroadsorbent Silicol®gel in Adults with Irritable Bowel Syndrome Subtypes IBS-D or Mixed: Observational Open-Label Study},
journal = {Gastroenterology Research and Practice},
year = {2023},
volume = {2023},
pages = {1--14},
doi = {10.1155/2023/3432763}
}
EUVIMED